DE602004023861D1 - Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden - Google Patents

Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden

Info

Publication number
DE602004023861D1
DE602004023861D1 DE602004023861T DE602004023861T DE602004023861D1 DE 602004023861 D1 DE602004023861 D1 DE 602004023861D1 DE 602004023861 T DE602004023861 T DE 602004023861T DE 602004023861 T DE602004023861 T DE 602004023861T DE 602004023861 D1 DE602004023861 D1 DE 602004023861D1
Authority
DE
Germany
Prior art keywords
patients suffering
oxcarbazepine
chronic pain
pain
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004023861T
Other languages
German (de)
English (en)
Inventor
Donald Manning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0320637A external-priority patent/GB0320637D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE602004023861D1 publication Critical patent/DE602004023861D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602004023861T 2003-09-03 2004-09-02 Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden Expired - Lifetime DE602004023861D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0320637A GB0320637D0 (en) 2003-09-03 2003-09-03 Organic compounds
US53737804P 2004-01-16 2004-01-16
PCT/EP2004/009797 WO2005020968A2 (en) 2003-09-03 2004-09-02 Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep

Publications (1)

Publication Number Publication Date
DE602004023861D1 true DE602004023861D1 (de) 2009-12-10

Family

ID=34276821

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004023861T Expired - Lifetime DE602004023861D1 (de) 2003-09-03 2004-09-02 Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden

Country Status (18)

Country Link
US (1) US20060270658A1 (https=)
EP (1) EP1663247B1 (https=)
JP (1) JP2007513056A (https=)
KR (1) KR20060118426A (https=)
AT (1) ATE446759T1 (https=)
AU (1) AU2004268381B2 (https=)
BR (1) BRPI0414112A (https=)
CA (1) CA2537060A1 (https=)
DE (1) DE602004023861D1 (https=)
IL (1) IL173822A0 (https=)
IS (1) IS8373A (https=)
MA (1) MA28036A1 (https=)
MX (1) MXPA06002392A (https=)
NO (1) NO20061515L (https=)
RU (1) RU2369393C2 (https=)
SG (1) SG146631A1 (https=)
TN (1) TNSN06072A1 (https=)
WO (1) WO2005020968A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
ES2360423T3 (es) * 2006-04-26 2011-06-03 Supernus Pharmaceuticals, Inc. Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal.
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
KR102486435B1 (ko) 2022-04-25 2023-01-10 주식회사 제이비플랜트 산업용 냉동기기의 친환경 패널의 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH500196A (de) 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
GB9930058D0 (en) 1999-12-20 2000-02-09 Novartis Ag Organic compounds
GB0128674D0 (en) * 2001-11-30 2002-01-23 Boots Co Plc Treatment of sleep disorders and the like
CA2497780A1 (en) * 2002-10-17 2004-04-29 Novartis Ag Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors

Also Published As

Publication number Publication date
MA28036A1 (fr) 2006-07-03
SG146631A1 (en) 2008-10-30
IL173822A0 (en) 2006-07-05
RU2006110550A (ru) 2007-12-20
AU2004268381B2 (en) 2009-06-18
WO2005020968A2 (en) 2005-03-10
JP2007513056A (ja) 2007-05-24
BRPI0414112A (pt) 2006-10-31
RU2369393C2 (ru) 2009-10-10
MXPA06002392A (es) 2006-06-20
AU2004268381A1 (en) 2005-03-10
CA2537060A1 (en) 2005-03-10
IS8373A (is) 2006-03-24
KR20060118426A (ko) 2006-11-23
EP1663247A2 (en) 2006-06-07
TNSN06072A1 (en) 2007-10-03
EP1663247B1 (en) 2009-10-28
NO20061515L (no) 2006-06-06
ATE446759T1 (de) 2009-11-15
WO2005020968A3 (en) 2005-05-19
US20060270658A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
SG152257A1 (en) Topical preparation containing ambroxol
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
RU2008127882A (ru) Лечение пищевода барретта
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
DE602004023861D1 (de) Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden
WO2005110413A3 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
DK1675611T3 (da) Terapeutiske anvendelser for C-peptid
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
NO20053032L (no) Anvendelse av 2,5-dihydroxybenzensulfoniske forbindelser for behandling av lidelser basert pa en forstyrrelse av NO produksjon og/eller av regulering av EDHF funksjon.
TW200515912A (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
TW200626133A (en) Oral medication for twice-daily administration
FR2853245B1 (fr) Utilisation du quinquina pour la preparation d'un medicament stimulant l'angiogenese
DE602006002126D1 (de) Verwendung von zinkgluconat zur behandlung von hydradenitis suppurativa
DE60120371D1 (de) Verwendung von wachstumshormon in niederen dosen
UA86416C2 (ru) Лекарственное средство, которое содержит n-сульфамоил-n'-арилпиперазины, предназначенное для профилактики или лечения ожирения и связанных с ним состояний
ATE442848T1 (de) Isoxazolsäure-derivat zur linderung neuropathischer schmerzen
SG163512A1 (en) Novel pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion

Legal Events

Date Code Title Description
8364 No opposition during term of opposition